Newark, DE, United States
Newark, DE, United States
SEARCH FILTERS
Time filter
Source Type

Patent
iBio Inc | Date: 2017-01-04

The present invention provides trans-complementation systems for expressing gene products in plants. In general, the invention provides systems including a carrier vector and a producer vector, both based on plant viruses. The producer vector is defective for at least one function needed for successful systemic infection of a plant, e.g., replication, cell-to-cell movement, or long distance movement. The carrier vector supplies the missing function in trans. Certain producer vectors lack a functional coat protein coding sequence, in which case the corresponding producer vector supplies coat protein in trans. The invention also provides novel plant viral vectors and methods of use, e.g., to produce polypeptides or active RNAs in plants.


NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE MKT:IBIO), a leader in developing plant-based biopharmaceuticals, announced today that Barry Holtz, PhD, President of iBio CMO LLC is scheduled to present the Company’s pharmaceutical development and production platforms during two sessions at the Plant-Based Vaccines, Antibodies & Biologics Conference in Albufeira, Portugal from June 5-7. Details of the Company’s plenary presentations are listed below. ‘cGmp manufacturing of a high molecular weight therapeutic protein-advantages of the PMP platform for downstream separations’ Monday, June 5, 5:30 PM – 5:50 PM WEST ‘A path forward for commercial acceptance of PMP: The fully integrated CDMO’ Tuesday, June 6, 4:05 PM – 4:20 PM WEST “This international conference provides an important forum to showcase advanced biologic platforms and products, and we look forward to engaging in a productive dialogue across the industry,” stated Dr. Holtz. “iBio’s presentations further reinforce the advantages of a plant-made pharmaceutical platform to deliver a novel and diverse set of solutions to biopharmaceutical companies, as well as the potential of our therapeutic candidate for fibrosis. Although most of our work for clients is confidential, our customers’ interests span a diverse range of product types including antibodies, growth factors, and vaccine antigens. During this conference, we will describe the benefits we offer customers such as these in shortening product development timelines and accelerating the advancement of their valuable product candidates.” iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CMO LLC in Bryan, Texas.  The facility houses laboratory and pilot-scale operations, as well as large-scale automated hydroponic systems capable of growing over four million plants as "in process inventory" and delivering over 300 kilograms of therapeutic protein pharmaceutical active ingredient per year. Facility capacity can be doubled by adding additional plant growth equipment in a space already reserved for that purpose. iBio applies its technology for the benefit of its clients and the advancement of its own product interests. The Company’s pipeline is comprised of proprietary candidates for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, based on the Company's proprietary gene expression technology, is the Company’s lead therapeutic candidate being advanced for IND development. Further information is available at:  www.ibioinc.com STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.


NEW YORK, June 05, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE MKT:IBIO), a leader in developing plant-based biopharmaceuticals, announced today that Barry Holtz, PhD, President of iBio CMO LLC is scheduled to present the Company’s pharmaceutical development and production platforms during two sessions at the Plant-Based Vaccines, Antibodies & Biologics Conference in Albufeira, Portugal from June 5-7. Details of the Company’s plenary presentations are listed below. ‘cGmp manufacturing of a high molecular weight therapeutic protein-advantages of the PMP platform for downstream separations’ Monday, June 5, 5:30 PM – 5:50 PM WEST ‘A path forward for commercial acceptance of PMP: The fully integrated CDMO’ Tuesday, June 6, 4:05 PM – 4:20 PM WEST “This international conference provides an important forum to showcase advanced biologic platforms and products, and we look forward to engaging in a productive dialogue across the industry,” stated Dr. Holtz. “iBio’s presentations further reinforce the advantages of a plant-made pharmaceutical platform to deliver a novel and diverse set of solutions to biopharmaceutical companies, as well as the potential of our therapeutic candidate for fibrosis. Although most of our work for clients is confidential, our customers’ interests span a diverse range of product types including antibodies, growth factors, and vaccine antigens. During this conference, we will describe the benefits we offer customers such as these in shortening product development timelines and accelerating the advancement of their valuable product candidates.” iBio, a leader in developing plant-based biopharmaceuticals, provides a range of product and process development, analytical, and manufacturing services at the large-scale development and manufacturing facility of its subsidiary iBio CMO LLC in Bryan, Texas.  The facility houses laboratory and pilot-scale operations, as well as large-scale automated hydroponic systems capable of growing over four million plants as "in process inventory" and delivering over 300 kilograms of therapeutic protein pharmaceutical active ingredient per year. Facility capacity can be doubled by adding additional plant growth equipment in a space already reserved for that purpose. iBio applies its technology for the benefit of its clients and the advancement of its own product interests. The Company’s pipeline is comprised of proprietary candidates for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, based on the Company's proprietary gene expression technology, is the Company’s lead therapeutic candidate being advanced for IND development. Further information is available at:  www.ibioinc.com STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.


Recombinant carrier molecules having amino acid sequences from thermostable enzymes and methods of use for expression, recovery and delivery of foreign sequences (peptides and polypeptides) produced in different systems (bacteria, yeast, DNA, cell cultures such as mammalian, plant, insect cell cultures, protoplast and whole plants in vitro or in vivo are provided. The recombinant carrier molecule using sequences from lichenase B (Lic B) were also made and used as part of carrier protein to express, recover and deliver a variety of target polypeptides of interest.


Antibodies against influenza neuraminidase, compositions containing the antibodies, and methods of using the antibodies are provided herein.


The present invention provides systems and methods for producing pharmaceutically active proteins in transgenic sprouted seedlings. The transgenic sprouted seedlings of the invention are grown in a contained, regulatable environment, wherein expression of a pharmaceutically active protein is controlled by an exogenously inducible promoter. The transgenic sprouted seedlings may be eaten live or preferably harvested live to preserve the maximal biological activity of the pharmaceutically active protein.


Patent
iBio Inc | Date: 2013-12-02

The present invention provides trans-complementation systems for expressing gene products in plants. In general, the invention provides systems including a carrier vector and a producer vector, both based on plant viruses. The producer vector is defective for at least one function needed for successful systemic infection of a plant, e.g., replication, cell-to-cell movement, or long distance movement. The carrier vector supplies the missing function in trans. Certain producer vectors lack a functional coat protein coding sequence, in which case the corresponding producer vector supplies coat protein in trans. The invention also provides novel plant viral vectors and methods of use, e.g., to produce polypeptides or active RNAs in plants.


Materials and methods for in vivo de-glycosylation of recombinant N-glycosylated proteins by co-expression with bacterial PNGase F (Peptide: N-glycosidase F) in plants, using a transient expression system are described. Methods are described which, for example, produce recombinant proteins of interest in plants in a non-glycosylated form. A method of expressing active bacterial PNGase F in plants also is provided.


Antibodies against influenza hemagglutinin, compositions containing the antibodies, and methods of using the antibodies are provided herein.


Patent
iBio Inc | Date: 2015-01-22

The present invention provides trans-complementation systems for expressing gene products in plants. In general, the invention provides systems including a carrier vector and a producer vector, both based on plant viruses. The producer vector is defective for at least one function needed for successful systemic infection of a plant, e.g., replication, cell-to-cell movement, or long distance movement. The carrier vector supplies the missing function in trans. Certain producer vectors lack a functional coat protein coding sequence, in which case the corresponding producer vector supplies coat protein in trans. The invention also provides novel plant viral vectors and methods of use, e.g., to produce polypeptides or active RNAs in plants.

Loading iBio Inc collaborators
Loading iBio Inc collaborators